Anaptys Announces Participation in September Investor Conferences
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on innovative immunology therapeutics, has announced its participation in three upcoming investor conferences in September 2024:
1. 2024 Wells Fargo Healthcare Conference in Boston, MA on Sept. 5 at 10:15am ET
2. Stifel 2024 Virtual Immunology and Inflammation Summit on Sept. 17 at 1:30pm ET
3. 2024 Cantor Fitzgerald Global Healthcare Conference in New York, NY on Sept. 18 at 9:45am ET
The company's president and CEO, Daniel Faga, and/or other senior management team members will participate in fireside chats and one-on-one investor meetings. Live webcasts of the fireside chats will be available on the Anaptys website, with replays accessible for at least 30 days after the events.
AnaptysBio, Inc. (Nasdaq: ANAB), una compagnia biotecnologica in fase clinica focalizzata su terapie innovative nell'immunologia, ha annunciato la sua partecipazione a tre conferenze per investitori in programma a settembre 2024:
1. Conferenza Sanitaria Wells Fargo 2024 a Boston, MA il 5 settembre alle 10:15 ET
2. Summit Virtuale su Immunologia e Infiammazione Stifel 2024 il 17 settembre alle 13:30 ET
3. Conferenza Sanitaria Globale Cantor Fitzgerald 2024 a New York, NY il 18 settembre alle 9:45 ET
Il presidente e CEO dell'azienda, Daniel Faga, e/o altri membri del team di alta direzione parteciperanno a colloqui informali e incontri individuali con gli investitori. Le trasmissioni in diretta dei colloqui informali saranno disponibili sul sito web di Anaptys, con repliche accessibili per almeno 30 giorni dopo gli eventi.
AnaptysBio, Inc. (Nasdaq: ANAB), una empresa biotecnológica en etapa clínica centrada en terapias innovadoras en inmunología, ha anunciado su participación en tres próximas conferencias para inversores en septiembre de 2024:
1. Conferencia de Atención Médica Wells Fargo 2024 en Boston, MA, el 5 de septiembre a las 10:15 a.m. ET
2. Cumbre Virtual de Inmunología e Inflamación de Stifel 2024 el 17 de septiembre a la 1:30 p.m. ET
3. Conferencia Global de Atención Médica Cantor Fitzgerald 2024 en Nueva York, NY, el 18 de septiembre a las 9:45 a.m. ET
El presidente y CEO de la compañía, Daniel Faga, y/o otros miembros del equipo de alta dirección participarán en charlas informales y reuniones individuales con inversores. Las transmisiones en vivo de las charlas informales estarán disponibles en el sitio web de Anaptys, con repeticiones accesibles durante al menos 30 días después de los eventos.
AnaptysBio, Inc. (Nasdaq: ANAB)는 혁신적인 면역학 치료제에 중점을 둔 임상 단계의 생명공학 회사로 2024년 9월에 열리는 세 가지 투자자 회의에 참석한다고 발표했습니다:
1. 2024 웰스파고 헬스케어 컨퍼런스가 9월 5일 오전 10시 15분 ET에 매사추세츠주 보스턴에서 열립니다.
2. 2024 스티펠 가상 면역학 및 염증 정상 회담이 9월 17일 오후 1시 30분 ET에 진행됩니다.
3. 2024 칸토르 피츠제럴드 글로벌 헬스케어 컨퍼런스가 9월 18일 오전 9시 45분 ET에 뉴욕주에서 열립니다.
회사의 대표이사이자 CEO인 다니엘 파가(Daniel Faga)와/혹은 다른 고위 관리 팀원이 비공식 대화 및 일대일 투자자 회의에 참여할 것입니다. 비공식 대화의 실시간 웹캐스트는 Anaptys 웹사이트에서 제공되며, 이벤트 종료 후 최소 30일 동안 재생이 가능합니다.
AnaptysBio, Inc. (Nasdaq: ANAB), une entreprise de biotechnologie en phase clinique axée sur des thérapies innovantes en immunologie, a annoncé sa participation à trois conférences pour investisseurs prévues en septembre 2024 :
1. Conférence sur les soins de santé Wells Fargo 2024 à Boston, MA le 5 septembre à 10h15 ET
2. Sommet virtuel sur l'immunologie et l'inflammation de Stifel 2024 le 17 septembre à 13h30 ET
3. Conférence mondiale sur la santé Cantor Fitzgerald 2024 à New York, NY le 18 septembre à 9h45 ET
Le président et PDG de l'entreprise, Daniel Faga, et/ou d'autres membres de l'équipe de direction participeront à des discussions informelles et à des réunions individuelles avec les investisseurs. Les diffusions en direct des discussions informelles seront disponibles sur le site Web d'Anaptys, avec des rediffusions accessibles pendant au moins 30 jours après les événements.
AnaptysBio, Inc. (Nasdaq: ANAB), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf innovative Immuntherapien konzentriert, hat seine Teilnahme an drei bevorstehenden Investorenkonferenzen im September 2024 angekündigt:
1. 2024 Wells Fargo Healthcare Conference in Boston, MA am 5. September um 10:15 Uhr ET
2. Stifel 2024 Virtuelles Immunologie- und Entzündungsgipfel am 17. September um 13:30 Uhr ET
3. 2024 Cantor Fitzgerald Globale Gesundheitskonferenz in New York, NY am 18. September um 9:45 Uhr ET
Der Präsident und CEO des Unternehmens, Daniel Faga, und/oder andere Mitglieder des Senior Management-Teams werden an informellen Gesprächen und persönlichen Investorenmeetings teilnehmen. Live-Webcasts der informellen Gespräche sind auf der Anaptys-Website verfügbar, und Wiederholungen sind für mindestens 30 Tage nach den Veranstaltungen zugänglich.
- Participation in multiple high-profile investor conferences
- Opportunity for direct engagement with investors through one-on-one meetings
- Live webcasts of fireside chats available for broader investor access
- None.
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences:
2024 Wells Fargo Healthcare Conference, Boston, MA
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Thursday, Sept. 5, 2024 at 10:15am ET / 7:15am PT
Stifel 2024 Virtual Immunology and Inflammation Summit
- Format – Fireside chat
- Date and Time – Tuesday, Sept. 17, 2024 at 1:30pm ET / 10:30am PT
2024 Cantor Fitzgerald Global Healthcare Conference, New York, NY
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Wednesday, Sept. 18, 2024 at 9:45am ET / 6:45am PT
Live webcasts of the fireside chats will be available on the investor section of the Anaptys website at http://ir.anaptysbio.com/events. Replays of the webcasts will be available for at least 30 days following the events.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics. It is developing immune cell modulators for autoimmune and inflammatory diseases, including two checkpoint agonists: ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis and rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. It also has other immune cell modulator candidates in its portfolio, including ANB033, an anti-CD122 antagonist antibody, entering a Phase 1 trial and ANB101, a BDCA2 modulator antibody, in preclinical development. In addition, Anaptys has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, that has completed Phase 3 trials for the treatment of generalized pustular psoriasis, and etokimab, an anti-IL-33 antagonist that is Phase 2/3 ready. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including an anti-PD-1 antagonist antibody (Jemperli (dostarlimab-gxly)) and an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889). To learn more, visit www.AnaptysBio.com or follow us on LinkedIn and X.
Contact:
Nick Montemarano
Senior Director, Investor Relations and Strategic Communications
858.732.0178
investors@anaptysbio.com
FAQ
What investor conferences will AnaptysBio (ANAB) attend in September 2024?
Who will represent AnaptysBio (ANAB) at the September 2024 investor conferences?
How can investors access AnaptysBio's (ANAB) presentations at the September 2024 conferences?
What type of company is AnaptysBio (ANAB)?
